AMP Capital Investors Ltd raised its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 6.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,773 shares of the biopharmaceutical company’s stock after purchasing an additional 2,020 shares during the quarter. AMP Capital Investors Ltd’s holdings in Regeneron Pharmaceuticals were worth $12,320,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC increased its position in shares of Regeneron Pharmaceuticals by 495.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 307 shares during the period. Advisory Services Network LLC boosted its stake in shares of Regeneron Pharmaceuticals by 147.0% during the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 266 shares in the last quarter. Vident Investment Advisory LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $200,000. Mackenzie Financial Corp bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $204,000. Finally, AE Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $206,000. 66.40% of the stock is currently owned by institutional investors.
Shares of Regeneron Pharmaceuticals Inc (NASDAQ REGN) opened at $337.75 on Wednesday. Regeneron Pharmaceuticals Inc has a one year low of $313.53 and a one year high of $543.55. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11. The company has a market cap of $36,290.00, a price-to-earnings ratio of 25.70, a PEG ratio of 1.07 and a beta of 1.54.
In other news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.80% of the company’s stock.
A number of equities analysts have recently issued reports on REGN shares. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Evercore ISI dropped their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a research note on Thursday, November 16th. BTIG Research reiterated a “buy” rating and set a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, November 27th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, November 28th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus target price of $449.49.
COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/03/14/regeneron-pharmaceuticals-inc-regn-position-increased-by-amp-capital-investors-ltd.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.